Yocell Biotechnology (Qingdao) Co., LTD

Recent advances in recombinant DNA technology have paved the way for the production of recombinant proteins that can be used as therapeutic drugs, vaccines and diagnostic reagents. Recombinant proteins for these applications are mainly produced using prokaryotic and eukaryotic expression host systems (e.g., mammalian cells, bacteria, yeast, insect cells, and transgenic plants) in both laboratory-scale and large-scale environments. The development of efficient bioprocessing strategies is essential for the industrial production of recombinant proteins with therapeutic and prophylactic implications.

Enzyme engineering is a science in which enzymes, enzyme containing organelles or cells (microorganisms, animals, plants) are used in certain reaction devices, using the biocatalytic function of enzymes, and using engineering means to convert corresponding raw materials into useful substances and used in social life. It includes preparation of enzyme preparation, solidification of enzyme, modification and transformation of enzyme and enzyme reactor. Its application is mainly concentrated in the pharmaceutical industry, food industry and light industry.

Filtration is widely used in biopharmaceutical manufacturing processes for the removal of process impurities and contaminants (particles, viruses) as well as the control of bioburden. The role of filtration has evolved as bioprocesses have moved towards intensification and the physical size and biochemical complexity of therapeutic products have increased. Optimising filtration steps to improve yield and product recovery while achieving acceptable process economics is now an increasing challenge. Collaboration between filtration technology suppliers, biopharmaceutical manufacturers and regulatory agencies is facilitating the development and adoption of new solutions to address these challenges.

The use of Single-Use Systems (SUS) in biopharmaceutical manufacturing has changed dramatically over the years. While we have seen a steady increase in the acceptance of SUS over the past few decades, COVID has created an environment that has accelerated the shift away from fixed stainless steel bioprocesses.

Unlike other active molecules, antitumour drugs have cytotoxicity issues and therefore need to be safely encapsulated and able to reach their target sites, all of which is made possible by the use of nanoparticles. In addition, nanoparticles have unique features such as loading of insoluble antineoplastic drugs, protection of the active fraction from harsh in vivo environments, sustained release, alteration of their biodistribution, targeting to specific cells/tissues and prolonged circulation time.

In the preparation process of nanomedicine, the use of ‌ microfluidization homogenizer can significantly improve the stability and safety of drugs. By adjusting the parameters such as ‌ homogeneous pressure and ‌ flow rate, ‌ can successfully prepare nanomedicines with uniform particle size distribution. ‌ these nanomedicines have not only good effect, but also high safety. ‌ This technology has broad application prospects in the field of medicine, ‌ especially in the need to improve the oral bioavailability of scenarios, such as ‌ to improve the oral bioavailability of omeprazole.